NCT00541983View on ClinicalTrials.gov

Single-dose, Dose-escalation Study of Safety, PK, and Preliminary Efficacy of XOMA 052 in Type 2 Diabetes Mellitus

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

July 31, 2009

Study Completion Date

February 28, 2010

Conditions
Type 2 Diabetes
Interventions
DRUG

XOMA 052

Subjects in six successive dose groups will receive a single IV infusion (mg/kg) of study drug on Day 0. The total time of the infusion will be 1 hour ± 15 minutes.

DRUG

Placebo

Subjects in six successive dose groups will receive a single IV infusion (mg/kg) of study drug on Day 0. The total time of the infusion will be 1 hour ± 15 minutes.

Trial Locations (2)

Unknown

Covance Clinical Research (formerly Swiss Pharma Contract), Allschwil

Zurich

All Listed Sponsors
lead

XOMA (US) LLC

INDUSTRY

NCT00541983 - Single-dose, Dose-escalation Study of Safety, PK, and Preliminary Efficacy of XOMA 052 in Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter